Protalix BioTherapeutics (PLX) Gains from Sales and Divestitures (2020 - 2025)

Protalix BioTherapeutics' Gains from Sales and Divestitures history runs 6 years deep, the most recent figure standing at $687232.0 for Q4 2025.

• In Q4 2025, Gains from Sales and Divestitures fell 30.74% year-over-year to $687232.0; the TTM figure through Dec 2025 stood at $687232.0 (down 30.74% YoY), while the FY2025 annual figure was $687232.0, down 30.74% from the prior year.
• Gains from Sales and Divestitures was $687232.0 for Q4 2025 at Protalix BioTherapeutics, up from $52910.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $992313.0 in Q4 2024 to a low of $52910.0 in Q3 2025.
• Historically, Gains from Sales and Divestitures has averaged $552368.2 across 5 years, with a median of $588199.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Gains from Sales and Divestitures jumped 456.0% in 2022, then plunged 47.18% in 2023.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $166553.0 in 2021, then surged by 456.0% to $926035.0 in 2022, then tumbled by 47.18% to $489166.0 in 2023, then jumped by 102.86% to $992313.0 in 2024, then plunged by 30.74% to $687232.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $687232.0 (Q4 2025), $52910.0 (Q3 2025), and $992313.0 (Q4 2024), per Business Quant data.